Page 12 - Secondary Progressive Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tiziana completes enrolment of first patient cohort in MS expanded access programme

Tiziana completes enrolment of first patient cohort in MS expanded access programme
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United statesGabriele cerroneTiziana life sciencesLife sciencesSecondary progressive multiple sclerosisExpanded disability status scale

Tiziana Life Sciences Ltd : Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel

United statesIrina kofflerHana malikGabriele cerroneTiziana life sciencesLifesci advisorsTiziana life sciences ltdPatient population expanded access programBusiness developmentLife sciencesSecondary progressive multiple sclerosisExecutive chairmanChief executive officerInvestor relationsSci advisors

New Guidance on Using High-Efficacy DMTs in Multiple Sclerosis

High-efficacy therapies for multiple sclerosis have improved disease outcomes for many patients, but physicians are uncertain when to use them.

Comunidad autonoma de catalunaRoche genentechMerck seronoGavin giovannoniPatricia coyleDalia rotsteinXavier montalbanEuropean academy of neurologyHebron university hospitalJazz pharmaceuticalsMerck coSclerosis centre of catalonia at vallUniversity of torontoSanofi aventisQueen mary university of londonBiogen idec

Stem Cell Transplant Trumps Fingolimod for RRMS Relapse Risk

Autologous hematopoietic stem cell transplantation is linked to significantly lower relapse rates than fingolimod in patients with relapsing-remitting multiple sclerosis. But adverse events are common.

Czech republicNew south walesTomas kalincikKubala havrdovEva kubala havrdovNeuroimmunology serviceResearch gapUniversity of melbourneSclerosis center at charles universityResearch in multiple sclerosisEuropean committee for treatmentEuropean committeeMultiple sclerosisMedscape medical newsRoyal melbourne hospitalMultiple sclerosis center

Tiziana Life Sciences Ltd : Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel

United statesIrina kofflerHana malikGabriele cerroneTanuja chitnisTiziana life sciencesLifesci advisorsTiziana life sciences ltdPatient population expanded access programAnn romney centerBusiness developmentLife sciencesSecondary progressive multiple sclerosisExecutive chairmanChief executive officerNeurologic diseases